S&P 500   3,678.94 (+0.27%)
DOW   30,064.96 (+0.61%)
QQQ   304.81 (+0.32%)
AAPL   123.03 (-0.04%)
MSFT   214.88 (-0.23%)
FB   283.63 (-1.35%)
GOOGL   1,827.01 (+0.11%)
AMZN   3,196.85 (-0.21%)
TSLA   593.78 (+4.39%)
NVDA   537.52 (-0.79%)
BABA   267.59 (+2.40%)
CGC   29.07 (+3.16%)
GE   10.64 (+2.01%)
MU   70.44 (+1.92%)
AMD   92.78 (-1.02%)
T   29.15 (+0.21%)
NIO   46.18 (-3.75%)
F   9.23 (+0.33%)
ACB   11.31 (+3.29%)
NFLX   497.92 (-1.08%)
BA   238.74 (+6.65%)
GILD   60.77 (-0.59%)
DIS   153.56 (-0.03%)
S&P 500   3,678.94 (+0.27%)
DOW   30,064.96 (+0.61%)
QQQ   304.81 (+0.32%)
AAPL   123.03 (-0.04%)
MSFT   214.88 (-0.23%)
FB   283.63 (-1.35%)
GOOGL   1,827.01 (+0.11%)
AMZN   3,196.85 (-0.21%)
TSLA   593.78 (+4.39%)
NVDA   537.52 (-0.79%)
BABA   267.59 (+2.40%)
CGC   29.07 (+3.16%)
GE   10.64 (+2.01%)
MU   70.44 (+1.92%)
AMD   92.78 (-1.02%)
T   29.15 (+0.21%)
NIO   46.18 (-3.75%)
F   9.23 (+0.33%)
ACB   11.31 (+3.29%)
NFLX   497.92 (-1.08%)
BA   238.74 (+6.65%)
GILD   60.77 (-0.59%)
DIS   153.56 (-0.03%)
S&P 500   3,678.94 (+0.27%)
DOW   30,064.96 (+0.61%)
QQQ   304.81 (+0.32%)
AAPL   123.03 (-0.04%)
MSFT   214.88 (-0.23%)
FB   283.63 (-1.35%)
GOOGL   1,827.01 (+0.11%)
AMZN   3,196.85 (-0.21%)
TSLA   593.78 (+4.39%)
NVDA   537.52 (-0.79%)
BABA   267.59 (+2.40%)
CGC   29.07 (+3.16%)
GE   10.64 (+2.01%)
MU   70.44 (+1.92%)
AMD   92.78 (-1.02%)
T   29.15 (+0.21%)
NIO   46.18 (-3.75%)
F   9.23 (+0.33%)
ACB   11.31 (+3.29%)
NFLX   497.92 (-1.08%)
BA   238.74 (+6.65%)
GILD   60.77 (-0.59%)
DIS   153.56 (-0.03%)
S&P 500   3,678.94 (+0.27%)
DOW   30,064.96 (+0.61%)
QQQ   304.81 (+0.32%)
AAPL   123.03 (-0.04%)
MSFT   214.88 (-0.23%)
FB   283.63 (-1.35%)
GOOGL   1,827.01 (+0.11%)
AMZN   3,196.85 (-0.21%)
TSLA   593.78 (+4.39%)
NVDA   537.52 (-0.79%)
BABA   267.59 (+2.40%)
CGC   29.07 (+3.16%)
GE   10.64 (+2.01%)
MU   70.44 (+1.92%)
AMD   92.78 (-1.02%)
T   29.15 (+0.21%)
NIO   46.18 (-3.75%)
F   9.23 (+0.33%)
ACB   11.31 (+3.29%)
NFLX   497.92 (-1.08%)
BA   238.74 (+6.65%)
GILD   60.77 (-0.59%)
DIS   153.56 (-0.03%)
Log in
ASX:BOT

Botanix Pharmaceuticals Limited (BOT.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.04
MA: A$0.04
A$0.04
52-Week Range N/A
Volume1.63 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+61-8-94820580
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.56 million
Book ValueA$0.02 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive BOT News and Ratings via Email

Sign-up to receive the latest news and ratings for BOT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Botanix Pharmaceuticals Limited (BOT.AX) (ASX:BOT) Frequently Asked Questions

What stocks does MarketBeat like better than Botanix Pharmaceuticals Limited (BOT.AX)?

Wall Street analysts have given Botanix Pharmaceuticals Limited (BOT.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Botanix Pharmaceuticals Limited (BOT.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Botanix Pharmaceuticals Limited (BOT.AX)'s earnings last quarter?

Botanix Pharmaceuticals Limited (BOT.AX) (ASX:BOT) issued its earnings results on Thursday, February, 28th. The company reported ($0.01) earnings per share for the quarter.
View Botanix Pharmaceuticals Limited (BOT.AX)'s earnings history
.

Who are some of Botanix Pharmaceuticals Limited (BOT.AX)'s key competitors?

What other stocks do shareholders of Botanix Pharmaceuticals Limited (BOT.AX) own?

Who are Botanix Pharmaceuticals Limited (BOT.AX)'s key executives?

Botanix Pharmaceuticals Limited (BOT.AX)'s management team includes the following people:
  • Mr. Vincent P. Ippolito, MD, Pres & Exec. Chairman (Age 61, Pay $808.16k)
  • Dr. Michael Thurn Ph.D., COO & Exec. Director
  • Dr. Henry William Bosch, Chief Scientific Officer & Exec. Director
  • Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB, Exec. Director (Age 47, Pay $481.08k)
  • Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA, Company Sec.

What is Botanix Pharmaceuticals Limited (BOT.AX)'s stock symbol?

Botanix Pharmaceuticals Limited (BOT.AX) trades on the ASX under the ticker symbol "BOT."

How big of a company is Botanix Pharmaceuticals Limited (BOT.AX)?

Botanix Pharmaceuticals Limited (BOT.AX) has a market capitalization of $0.00 and generates $7.56 million in revenue each year. Botanix Pharmaceuticals Limited (BOT.AX) employs 1 workers across the globe.

What is Botanix Pharmaceuticals Limited (BOT.AX)'s official website?

The official website for Botanix Pharmaceuticals Limited (BOT.AX) is www.botanixpharma.com.

How can I contact Botanix Pharmaceuticals Limited (BOT.AX)?

Botanix Pharmaceuticals Limited (BOT.AX)'s mailing address is Ground Floor, 16 Ord St, PERTH, WAS 6005, Australia. The company can be reached via phone at +61-8-94820580.

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.